Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siew Eng Choon

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Dermatology and Therapy|April 4, 2025
Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological ConditionsKenneth B Gordon, Yayoi Tada, Milan J Anadkat, et al.
The British Journal of Dermatology|January 23, 2025
Global Delphi consensus on treatment goals for generalized pustular psoriasisJonathan N Barker, Emmylou Casanova, Siew Eng Choon, et al.
The New England Journal of Medicine|March 12, 2019
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular PsoriasisHervé Bachelez, Siew-Eng Choon, Slaheddine Marrakchi, et al.
JAMA Dermatology|April 6, 2013
Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional studyAmy S Paller, Katherine Mercy, Mary J Kwasny, et al.
Clinical Immunology (Orlando, Fla.)|February 4, 2023
DNA methylation of ITGB2 contributes to allopurinol hypersensitivityYu Liu, Chuang-Wei Wang, Chun-Bing Chen, et al.
The Journal of Investigative Dermatology|July 14, 2024
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1Ahmed Farag, Sudha Visvanathan, Hervé Bachelez, et al.
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
BMJ Open|March 31, 2021
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareSiew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, et al.
The Journal of Investigative Dermatology|September 21, 2019
IL-36 Promotes Systemic IFN-I Responses in Severe Forms of PsoriasisMarika Catapano, Marta Vergnano, Marco Romano, et al.
The British Journal of Dermatology|April 19, 2023
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activityA David Burden, Hervé Bachelez, Siew Eng Choon, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Dermatology and Therapy|April 4, 2025
Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological ConditionsKenneth B Gordon, Yayoi Tada, Milan J Anadkat, et al.
The British Journal of Dermatology|January 23, 2025
Global Delphi consensus on treatment goals for generalized pustular psoriasisJonathan N Barker, Emmylou Casanova, Siew Eng Choon, et al.
The New England Journal of Medicine|March 12, 2019
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular PsoriasisHervé Bachelez, Siew-Eng Choon, Slaheddine Marrakchi, et al.
JAMA Dermatology|April 6, 2013
Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional studyAmy S Paller, Katherine Mercy, Mary J Kwasny, et al.
Clinical Immunology (Orlando, Fla.)|February 4, 2023
DNA methylation of ITGB2 contributes to allopurinol hypersensitivityYu Liu, Chuang-Wei Wang, Chun-Bing Chen, et al.
The Journal of Investigative Dermatology|July 14, 2024
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1Ahmed Farag, Sudha Visvanathan, Hervé Bachelez, et al.
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
BMJ Open|March 31, 2021
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareSiew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, et al.
The Journal of Investigative Dermatology|September 21, 2019
IL-36 Promotes Systemic IFN-I Responses in Severe Forms of PsoriasisMarika Catapano, Marta Vergnano, Marco Romano, et al.
The British Journal of Dermatology|April 19, 2023
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activityA David Burden, Hervé Bachelez, Siew Eng Choon, et al.
Pageof 7